Compare Quest Diagnostics Inc (DGX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tripadvisor Inc Common Stock — how do they compare? Quest Diagnostics Inc trades at $204.59 (market cap $22.80B), while Tripadvisor Inc Common Stock trades at $14.52 (market cap $1.63B). The key difference: Quest Diagnostics Inc is far larger — about 14× Tripadvisor Inc Common Stock's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| DGX | TRIP | |
|---|---|---|
Market Cap | $22.80B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $19.14 |
52-Week Low | $166.42 | $9.24 |
Enterprise Value | $28.82B | $1.75B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Tripadvisor (TRIP) trades at $14.40, up 3.0% today, with technical indicators showing bullish momentum. The company reported mixed Q2 2026 earnings, missing expectations in two of the last three quarters. Recent news highlights the $700 million sale of TheFork to American Express, which may provide capital flexibility. Revenue grew to $1.89 billion in 2025, though net margins remain thin at 0.99%. Analyst consensus is mixed with 60.7% hold ratings and a $13.87 price target slightly below current levels.
The outlook is cautious due to competitive pressures and inconsistent earnings, but the stock shows technical strength. Opportunities include potential benefits from the TheFork sale and travel sector recovery. Key risks are macroeconomic headwinds and execution challenges in core segments. Investors should weigh solid cash flow against high P/E valuation and analyst skepticism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
